Welfo Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 8.00 M
- Paid Up Capital ₹ 8.00 M
- Company Age 26 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.67 Cr
- Revenue Growth -58.34%
- Profit Growth -95.46%
- Ebitda -61.65%
- Net Worth
- Total Assets 35.97%
About Welfo Pharmaceutical
Welfo Pharmaceutical Private Limited (WPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 February 1998 and has a history of 26 years and 11 months. Its registered office is in 24 Pgs (S), West Bengal.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 8.00 M and a paid-up capital of Rs 8.00 M.
The company currently has active open charges totaling ₹1.67 Cr.
Sutapa Chakraborty and Biswanath Chakraborty serve as directors at the Company.
Company Details
-
Location24 Pgs (S), West Bengal
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239WB1998PTC086516
-
Company No.
086516
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Feb 1998
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Welfo Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sutapa Chakraborty
|
Director | 09-Feb-1998 | Current |
|
Biswanath Chakraborty
|
Director | 26-Apr-2013 | Current |
Financial Performance of Welfo Pharmaceutical.
Welfo Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 58.34% decrease. The company also saw a substantial fall in profitability, with a 95.46% decrease in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Welfo Pharmaceutical?
In 2020, Welfo Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹16.67 M
₹0
Charges Breakdown by Lending Institutions
- United Bank Of India : 1.67 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Mar 2005 | United Bank Of India | ₹1.67 Cr | Open |
How Many Employees Work at Welfo Pharmaceutical?
Unlock and access historical data on people associated with Welfo Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Welfo Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Welfo Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
